{"id":"NCT00722137","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma","officialTitle":"A Randomized, Open-Label, Multicenter Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05-01","primaryCompletion":"2014-01-01","completion":"2017-06-17","firstPosted":"2008-07-25","resultsPosted":"2014-11-17","lastUpdate":"2018-07-12"},"enrollment":487,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Mantle Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Rituximab 375 mg/m^2","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide 750 mg/m^2","otherNames":[]},{"type":"DRUG","name":"Doxorubicin 50 mg/m^2","otherNames":[]},{"type":"DRUG","name":"VELCADE 1.3 mg/m^2","otherNames":[]},{"type":"DRUG","name":"Prednisone 100 mg/m^2","otherNames":[]},{"type":"DRUG","name":"Vincristine 1.4 mg/m^2","otherNames":[]}],"arms":[{"label":"R-CHOP","type":"ACTIVE_COMPARATOR"},{"label":"VcR-CAP","type":"EXPERIMENTAL"}],"summary":"This is a randomized, open-label, multicenter, prospective study to compare the efficacy and safety of the combination of VcR-CAP to that of R-CHOP in participants who have newly diagnosed mantle cell lymphoma grade II, III or IV and who are ineligible to undergo bone marrow transplantation.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"Median duration of follow-up of 40 months","effectByArm":[{"arm":"R-CHOP","deltaMin":437,"sd":null},{"arm":"VcR-CAP","deltaMin":751,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":16,"exclusionCount":11},"locations":{"siteCount":150,"countries":["United States","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Germany","Hungary","India","Israel","Italy","Malaysia","Morocco","Philippines","Poland","Portugal","Romania","Russia","Singapore","South Africa","Spain","Taiwan","Thailand","Tunisia","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["30348538","28583031","28183846","25738670"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":72,"n":242},"commonTop":["Nausea","Cough","Alopecia","Insomnia","Neuropathy peripheral"]}}